Pentoxyfylline
(Die Seite wurde neu angelegt: „{{up|PHA conventional pharmacology}} {{tp|p=32449676|t=2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.|pdf=|usr=007}} {{tp|p=32473070|t=2020…“)
Aktuelle Version vom 12. April 2021, 15:34 Uhr
| PHA conventional pharmacology |
32449676 2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.
32473070 2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
32485316 2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.
32540603 2020. Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19.
32946870 2020. Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic.
33049737 2020. Pentoxifylline, a drug with antiviral, anti-inflammatory and bronchodilatory effects may be a possible drug candidate for SARS-CoV-2.
33278747 2020. Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study.
32706089 2020. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2.
32715661 2020. Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.
32754467 2020. COVID-19: Older drugs for a novel disease-Chloroquine, hydroxychloroquine, and possible Pentoxifylline-set to start the second innings?
32787748 2020. Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the "Cytokine Release (Storm) Syndrome" Caused by SARS-CoV-2?
